A Phase 4 interventional study of Folinic acid in NSCLC, Mesothelioma and Thymoma, sponsored by Amphia Hospital. Recruiting at 2 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-24.
Sponsored by Amphia Hospital · Phase 4, Interventional, and Prevention
Objective The main objective is to evaluate the haematological toxicity in patients who use pemetrexed with and without rescue therapy with folinic acid.
Primary endpoint Difference between treatment groups in neutrophil count (*109/L) at day 8-10 after administration of pemetrexed (nadir).
Secondary endpoints The grade neutropenia (according to the CTCAE version 5, 2017) at day 8-10, the homocysteine plasma levels at baseline (predictor for developing toxicity), the efficacy of chemotherapy treatment based on response CT after cycle 2 and 4 and the incidence of discontinuation, dose delays and dose reductions of pemetrexed.
Trial design The FLEX-trial is a multi-centre, open label, double arm, randomized trial to compare neutropenia in patients with and without folinic acid rescue therapy where subjects are participating for 4 treatment cycles.
Population In total 50 patients (25 in each arm), >18 years with stage IV non-small cell lung cancer (NSCLC) or mesothelioma treated with pemetrexed (in combination with other chemo- or immunotherapy) are eligible for inclusion.
Interventions Follow-up will take place during the first 4 cycles of chemotherapy with pemetrexed. Patients in the intervention-arm will receive oral folinic acid orally 4 times 45mg / day for 3 days, starting 24 hours after the administration of pemetrexed.
In order to be eligible to participate in this study, a subject must meet all of the following criteria:
A potential subject who meets any of the following criteria will be excluded from participation in this study:
Contraindications for treatment with folinic acid in line with the SmPC.
Patients in the intervention-arm will receive oral folinic acid orally 4 times 45mg / day for 3 days, starting 24 hours after the administration of pemetrexed.
Drug: Folinic acid
Patients will be treated according to regular care.
Follow-up will take place during the first 4 cycles of chemotherapy with pemetrexed. Patients in the intervention-arm will receive oral folinic acid orally 4 times 45mg / day for 3 days, starting 24 hours after the administration of pemetrexed.
Difference in neutrophil count (*109/L) at day 8-10 after pemetrexed administration during 2 cycles of chemotherapy
To evaluate the haematological toxicity (continuous measure) in patients who use pemetrexed with and without rescue therapy with folinic acid.
Time frame: Between day 8-10 in the first 2 cycles (each cycle is 21 days)
Grade neutropenia (according to the CTCAE version 5, 2017) at day 8-10 after pemetrexed administration during 2 cycles of chemotherapy
To evaluate the difference in haematological toxicity based on the CTCAE criteria for neutrophil count
Time frame: Between day 8-10 in the first 2 cycles (each cycle is 21 days)
Homocysteine plasma levels at baseline (μmol/L)
To evaluate the influence of baseline homocysteine plasma levels on occurrence of haematological toxicity.
Time frame: Once, before the start of the first cycle (each cycle is 21 days)
Efficacy based on response CT after cycle 2 and 4 (categorical: response, partial response, progression)
To evaluate the efficacy of the treatment with pemetrexed (based on CT-scan).
Time frame: After the second and fourth cycle (each cycle is 21 days)
Incidence of discontinuation, dose delays and dose reductions of pemetrexed
To evaluate the incidence of treatment delay or dose reduction of pemetrexed.
Time frame: 3 months
Documents are hosted by the registry — open the source record to download them.
Plan to share: Undecided
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amphia Hospital